Search

everythinglearnresearchcommunity

for

Search:↓

Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.

Lowering testosterone speeds up wound healing in male mice.

COVID-19 can cause temporary hair loss, which is commonly reversible with treatment.

Androgen replacement therapy can improve libido and mood in women with severe androgen deficiency, but more research is needed on its long-term safety.

The guidelines advise against using testosterone and DHEA in women for most conditions due to safety and effectiveness concerns, but suggest considering testosterone for postmenopausal women with low sexual desire.

Hormonal treatments can help with hair loss, acne, and excess hair growth, but it takes 3-6 months to see results and patients should know the possible side effects.

Short-term testosterone therapy in women seems safe with few mild side effects, but long-term effects need more research.

Menopause often leads to lower sexual desire and discomfort during sex, but treatment should be personalized and only if it bothers the woman.

Hormonal imbalances during menopause may significantly contribute to Frontal Fibrosing Alopecia.

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

Primary care doctors should address female sexual dysfunctions to improve women's sexual health and life quality.

Men generally have more severe COVID-19 cases and higher death rates than women due to biological differences.

Testosterone therapy may slightly increase sexual desire in women with HSDD but lacks broad recommendation due to safety concerns and limited approval.

Genetic factors affect hair loss, and molecular testing may help predict, diagnose, and treat it.

Finasteride shows promise for female hair loss, but more research needed.

Testosterone therapy can improve sexual desire and function in postmenopausal women but should be used cautiously and not based solely on testosterone levels.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

DHEA may help with sexual function when used intravaginally by menopausal women but is similar to hormone therapy in other aspects and might cause more side effects like acne and hair loss.

The report recommends personalized treatment for women's sexual dysfunctions and more research on effective therapies.

The NAMS 2014 recommendations guide healthcare providers on treating health issues in midlife women, emphasizing individualized care and informed decision-making.

Erosive pustular dermatosis in elderly people may be linked to aging immune systems and skin damage.

The document concludes that low-dose oral contraceptives and hormonal therapies can manage perimenopause symptoms and reduce some health risks, but lifestyle changes and disease screening are also important.

Minoxidil may work for hair loss by reducing androgen sensitivity and altering hormone-related enzymes.

Both minoxidil-spironolactone and minoxidil-finasteride treatments work for hair loss, but minoxidil-spironolactone is slightly more effective, especially in women.

Alopecia X in dogs is a cosmetic issue, not a hormonal disorder, and harmful treatments should be avoided.

Treat pattern hair loss with finasteride and topical minoxidil.

Older adults diagnosed with lupus show less severe symptoms but have a lower survival rate, often due to age-related factors.

Topical minoxidil is the most promising treatment for male pattern hair loss, but more research is needed to confirm its effectiveness and safety.

The document concludes that skin aging in women can be caused by UV exposure and hormonal changes, and treatments like hormone replacement therapy and various skin therapies can help.

Male and female skin differ due to hormones, affecting conditions like hair loss, acne, and skin cancer, and suggesting a need for gender-specific treatments.